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Abstract 
 
Background: The nitric oxide synthase 1 adaptor protein gene (NOS1AP) has previously been 
recognised as a schizophrenia susceptibility gene due to its role in glutamate 
neurotransmission.  The gene is believed to inhibit nitric oxide (NO) production activated by 
the N-methyl-D-aspartate (NMDA) receptor and reduced NO levels have been observed in 
schizophrenia patients.  However, association studies investigating NOS1AP and 
schizophrenia have produced inconsistent results, most likely because schizophrenia is a 
clinically heterogeneous disorder.  This study aims to investigate the association between 
NOS1AP variants and defined depression phenotypes of schizophrenia. 
Methods: Nine NOS1AP SNPs, rs1415259, rs1415263, rs1858232, rs386231, rs4531275, 
rs4656355, rs4657178, rs6683968 and rs6704393 were genotyped in 235 schizophrenia 
subjects screened for various phenotypes of depression. 
Result: One NOS1AP SNP (rs1858232) was associated with the broad diagnosis of 
schizophrenia and eight SNPs were associated with depression related phenotypes within 
schizophrenia.  The rs1415259 SNP showed strong association with sleep dysregulation 
phenotypes of depression. 
Conclusion: Results suggest that NOS1AP variants are associated with various forms of 
depression in schizophrenia and are more prevalent in males.   
Limitation: Schizophrenia is a clinically heterogeneous disease that can vary greatly between 
different ethnic and geographic populations so our observations should be viewed with 
caution until they are independently replicated, particularly in larger patient cohorts. 
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Introduction 
 
Schizophrenia is a heterogeneous disorder that was classically identified under Diagnostic 
and Statistical Manual of Mental Disorders Fifth Edition (DSM-V) criteria by screening 
patients for hallucinations, delusions, neuromuscular dysfunction and negative symptoms.  In 
many cases however, the symptomatology of schizophrenia usually extends to include 
various comorbid disorders including but not limited to depression, substance abuse, social 
phobia, posttraumatic stress disorder and obsessive compulsive disorder. Depression has been 
known to have high prevalence not just in schizophrenia but in other psychiatric disorders.  In 
fact, the Australian Department of Health reported a 54.5% rate of comorbid depression in 
people with psychosis (Morgan et al., 2011).  The high prevalence of depression within 
psychosis suggests an overlapping molecular pathophysiology that underlines both 
conditions.   
 
The NOS1AP gene encodes nitric oxide synthase 1 adaptor protein that binds to signalling 
molecule neuronal nitric oxide synthase (nNOS) which is involved in downstream 
glutamatergic signalling in the postsynaptic density.  Activation of the NMDA receptor 
causes a cascade that recruits nNOS and PSD-95 (post-synaptic density protein-95) serving as 
the anchor between nNOS and the NMDA receptor.  Sustained activation of the NMDA 
receptor allows calcium influx which activates the nNOS for NO production (Brenman et al., 
1996; Doucet et al., 2012; Nedvetsky et al., 2002).  NOS1AP competes with PSD-95 for 
nNOS binding hence reducing the interaction between PSD-95 and nNOS (Jaffrey et al., 
1998) and changes the NO production activity.  Changes in cellular NO levels have also been 
reported to be associated with various psychiatric conditions such as depression, 
schizophrenia, bipolar disorder and cognitive deficits, see review (Freudenberg et al., 2015).  
This places NOS1AP as a component within the downstream neuropathology of glutamate 
neurotransmission as glutamate signalling has long been implicated in schizophrenia and 
various psychiatric symptoms (Coyle et al., 2003; Lang et al., 2007).   
 
Animal studies suggest that NOS1AP acts as a facilitator (instead of inhibitor) for NMDAR-
mediated cellular cascades (Cheah et al., 2006; Fang et al., 2000; Li et al., 2013).  
Antidepressant effects were reported in animal models when glutamate activity was reduced 
via small-molecule inhibition of nNOS-PSD95-NMDAR complex (Doucet et al., 2013).  
Another similar animal study also reported antidepressant effects by glutamate activity 
reduction via small-molecule dissociation of NOS1AP-nNOS complex (Zhu et al., 2014).  
These studies suggest a positive relationship between NOS1AP and nNOS activity that 
increases NO and glutamate activity, promoting depressive effects. 
 
Although the number of association studies between NOS1AP and schizophrenia are limited, 
there is still sufficient evidence to support the role of NOS1AP in schizophrenia.  Brzustowicz 
and colleagues previously identified linkage in chromosome region 1q-21-22 (encompassing 
the NOS1AP gene) in two Canadian family studies (Brzustowicz et al., 2002; Brzustowicz et 
al., 2000).  A subsequent follow-up study identified a functional SNP (rs12742393) in the 
promoter that exhibited strong linkage disequilibrium (LD) with schizophrenia and was 
associated with high levels of NOS1AP expression in prefrontal cortex of post-mortem 
schizophrenia brain samples (Wratten et al., 2009).  The functional SNP is believed to alter 
affinity for binding of nuclear proteins.  This suggests that differential transcription factor 
binding may be the mechanism responsible for differential expression between alleles.  In a 
South American study, one SNP (rs6680461) was found associated with schizophrenia and 
further transmission disequilibrium test analysis revealed that the SNP was over-transmitted 
in schizophrenia patients with negative symptoms (including avolition and social isolation) 
(Kremeyer et al., 2009).  A Chinese Han population study reported an association between 
rs348624 and schizophrenia (Zheng et al., 2005).  SNP rs348624 is a synonymous 
polymorphism located in exon 9 that is in strong LD with a nearby splice site SNP 
(rs11422090) as well as other neighbouring functional SNPs that alter transcription and 
splicing (Zheng et al., 2005).  However, several studies failed to detect association between 
NOS1AP and schizophrenia (Fang et al., 2008; Nicodemus et al., 2008; Puri et al., 2006).  A 
recent meta-analysis of three pooled European samples (German, Swedish and Spanish) 
could not find association between NOS1AP SNPs and schizophrenia; but when the three 
sample sets were analysed independently association between NOS1AP SNPs and 
schizophrenia was found (Weber et al., 2014). 
 
The nitric oxide synthase 1 adaptor protein (NOS1AP) gene is a schizophrenia susceptibility 
gene that is implicated in other psychiatric conditions including depression, autism spectrum 
disorders, impulsivity and cognitive deficits, see review (Freudenberg et al., 2015).  Since we 
previously identified an association between NOS1AP and depression in a cohort of 
posttraumatic stress disorder patients (Lawford et al., 2013), in the present study we have 
examined association with depression in a cohort of schizophrenia patients to further 
understand the role of NOS1AP in various depression phenotypes in schizophrenia. 
 
Methods 
 
Subjects 
 
Schizophrenia cases 
The participants were obtained from the Australian Schizophrenia Research Bank (ASRB: 
www.schizophreniaresearch.org.au).  They consisted of 235 schizophrenia patients of 
European descent with a mean age of 43.9 years (sd ± 10.7 years).  There were 70 females 
and 165 males with a confirmed diagnosis of schizophrenia according to DSM-IV/ICD-10 
diagnostic criteria with a mean onset age of 23.18 years (sd ± 6.31 years).  The demographic 
history of participants is detailed in Table 1.  All participants underwent a clinical and 
neuropsychological assessment and provided a blood sample at the time of assessment.  The 
participants were assessed using a clinical assessment battery that consists of the Diagnostic 
Interview for Psychosis (DIP) (Castle et al., 2006) to collect socio-demographic, family and 
medical history data, and clinical measures for lifetime occurrence of various depression 
phenotypes (clinical measure details can be found in Supplementary Table 1).  The 
depression phenotype measures are defined by the DIP which covers various forms of 
depression that can be expressed by patients.  All schizophrenia patients and controls were 
recruited from several sources across five Australian States and Territories (New South 
Wales, Australian Capital Territory, Queensland, Western Australia and Victoria) using 
media advertisements, inpatient, outpatient and community mental health service providers, 
non-government organisations and rehabilitation services.  All participants identified 
themselves as having European decent.  In this case the definition of European covered a very 
large and diverse region spanning from as far north and south as Norway and southern Italy 
and as far west as Ireland and east as far as Turkey but excluding Middle Eastern Europe.  
Australians of Aboriginal or Torres Strait Island decent were excluded.     
 
Controls 
The control group was also obtained from the ASRB.  The controls consisted of 121 females 
and 104 males of European descent, with a mean age of 45.00 years (s.d. ± 13.2 years).  
Healthy controls were screened for a family history of, or treatment for, a psychiatric illness 
at the time of registration.  The controls were assessed using a clinical assessment battery that 
consists of the Diagnostic Interview for Psychosis (DIP) (Castle et al., 2006) to collect socio-
demographic, family and medical history data.  They provided a blood sample at time of 
assessment.  
 
Ethics 
Each participant gave written informed consent before commencement of data collection.  
Ethics approval for the project was obtained from the Human Research Ethics Committee of 
the Queensland University of Technology.  This study was carried out in accordance with 
The Code of Ethics of the World Medical Association (Declaration of Helsinki). 
 
SNP Genotyping 
DNA was provided by the ASRB.  NOS1AP tag-SNPs were selected using HapMap project 
phase 2 (International HapMap, 2003) with a minor allele frequency cut-off of 0.15 and were 
identified using pair-wise option of Tagger with r2 > 0.8 threshold.  NOS1AP tag-SNPs 
included rs1415259, rs1415263, rs1858232, rs386231, rs4531275, rs4656355, rs4657178, 
rs6683968 and rs6704393.  Samples were genotyped for the NOS1AP SNPs using a 
homogeneous MassEXTEND (hME) Sequenom assay performed by the Australian Genome 
Research Facility (AGRF). The hME assay is based on the annealing of a hME primer 
adjacent to the targeted SNP.  Addition of DNA polymerase and terminator nucleotide 
mixture allows the extension of the hME primer through the SNP site, thus generating allele-
specific extension products with a unique molecular mass.  The mass of the extension 
products were analysed with matrix-assisted laser desorption/ionisation time-of-flight mass 
spectrometry (MALDI-TOF MS) to determine a genotype. 
 
Statistical Analysis 
SNP-schizophrenia association was analysed by likelihood ratio chi-square using Statistical 
Package for the Social Sciences (SPSS) version 21 to compare genotype frequencies between 
schizophrenia and control groups.  SNP-phenotype association was analysed by ANOVA 
(analysis of variance) using SPSS version 21 to detect measure mean score differences 
between genotypes in schizophrenia patients.  A higher measure score means a higher clinical 
severity for a clinical measure.  Hardy-Weinberg equilibrium was tested using Utility 
Programs for Analysis of Genetic Linkage (Ott, 1988).  Power calculations for SNP-
schizophrenia association was performed using Mann-Whitney power calculator from the 
Compare2 software package (Abramson, 2004) that screens power from genotype 
frequencies in a pool of schizophrenia and controls at a desired odds ratio.  Power 
calculations for SNP-phenotype association was performed using the Power and Sample 
Size.com ANOVA Power Calculator (http://powerandsamplesize.com/Calculators/Compare-
k-Means/1-Way-ANOVA-Pairwise) that screens power from pairwise comparisons for three 
genotypes per SNP and calculates the genotype counts required to achieve 80% power to 
detect a significant variance between two genotypes for each phenotype.  Post-hoc Tukey’s 
test was performed on SNPs found associated with depression phenotypes to identify 
significant differences between genotype pairs for all SNP-depression phenotype 
associations.  Correction for multiple testing of SNP-schizophrenia association and SNP-
phenotype associations for each phenotype was performed using the Benjamini-Hochberg 
method (Benjamini and Hochberg, 1995).  SNPs found associated with a depression 
phenotypes were followed by dominance model analysis to determine the mode of 
inheritance of alleles.  Males and females were also analysed separately to identify SNP-
phenotype associations influenced by sex. 
 
Results 
All SNPs were found to be in Hardy-Weinberg equilibrium (P > 0.05).  Power calculations 
for SNP-schizophrenia association revealed that all nine SNPs in the study have an 80% 
chance to detect an association with schizophrenia at 1.8 odds ratio.  Power calculations for 
SNP-phenotype association revealed that all nine SNPs have an 80% chance to detect an 
association with between one to four depression phenotypes for each SNP. 
 
Case Control Association Study 
Genotypes for nine NOS1AP SNPs were determined in 225 controls and 235 schizophrenia 
cases.  Out of the nine SNPs tested only one (rs1858232) was associated with schizophrenia 
with a P-value of 0.041 (Table 2), which was only marginally significant and was not 
significant after correction for multiple testing (P = 0.041, q = 0.006). 
 
Phenotype-SNP Association Study 
To test for association between NOS1AP and depression in a cohort of schizophrenia patients, 
ANOVAs between DIP depression measures and nine NOS1AP SNPs were performed.  
SNPs rs1415259, rs1415263, rs1858232, rs4531275, rs4656355, rs4657178, rs6683968 and 
rs6704393 all showed association with at least one depression related phenotype (Table 3).  
SNP rs386231 was not associated with any depression phenotypes. 
 
Tukey’s test for each SNP found all but one SNP survived post-hoc analysis.  The association 
between depressive poor appetite and rs4531275 did not survive post-hoc analysis.   
Correction for multiple testing found that the association between rs4657178 and “depressive 
delusions of poverty” (P = 0.002, q = 0.006) survived multiple testing correction.  No other 
associations survived correction.  Additionally, analysis to determine the mode of inheritance 
for each SNP was performed for SNPs that survived Tukey’s post-hoc test with a P-value < 
0.05 (Table 3). 
 
Interestingly, rs1415259 is associated with sleep-related depression phenotypes while other 
SNPs are associated with either a single depression phenotype or multiple but unrelated 
depression phenotypes. 
 
Sex Effects on Phenotype-SNP Associations 
Depression often shows strong sex effects so sex association tests were performed for all 
SNPs to determine if the depressive phenotypes have sex-specific effects.  SNPs that were 
associated with depressive phenotypes in males are: rs1415259 (P = 0.028 for interrupted 
sleep form depressive insomnia, P = 0.020 for early waking form depressive insomnia); 
rs1415263 (P = 0.044 for depressive slowed activity); rs4531275 (P = 0.038 for depressive 
slowed activity, P = 0.007 for depressive poor appetite, P = 0.007 for depressive delusions of 
poverty); rs4657178 (P = 0.002 for depressive delusions of poverty); rs6683968 (P = 0.011 
for depressive delusions of poverty) and rs6704393 (P = 0.025 in depressive excessive self-
guilt).  SNPs that were associated with depressive phenotypes in females are rs1858232 (P = 
0.008 for depressive weight gain) and rs4656355 (P = 0.047 for interrupted sleep form 
depressive insomnia). 
 
 
Discussion 
 The present study tested association between nine NOS1AP SNPs and various phenotypes of 
depression in schizophrenia patients.  These SNPs are not associated with schizophrenia but 
do show association with multiple forms of depression in schizophrenia.  Our sample consists 
of a mixed European population which is ethnically diverse and genetically heterogeneous.  
The use of a genetically heterogeneous population should decrease the possibility of 
population stratification but decrease the chance of finding genetic associations.  Despite this 
limitation, we were still able to find association between eight NOS1AP SNPs and several 
depression phenotypes.  These depression phenotypes appear to be related to energy drive 
and motivation, appetite, sleep, and logical process leading to delusions and guilt in these 
patients, suggesting that these features may share a common pathophysiology linked to 
depression in schizophrenia patients.  In light of our previous finding of association with 
depression in combat veterans with posttraumatic stress disorder (Lawford et al., 2013), our 
present results further suggest a role for NOS1AP in depression that is not limited to 
schizophrenia. 
 
A recent genome-wide schizophrenia association study (GWAS) found no association with 
rs1858232; but found nominal association with another NOS1AP SNP rs1415263 (P = 0.023) 
(Schizophrenia Working Group of the Psychiatric Genomics, 2014).  The discordant results 
are possibly due to sample size differences as the association found between rs1858232 and 
schizophrenia was only marginally significant and did not hold up after multiple correction.  
The difference could also be due to population make-up as the genome-wide study sample 
consists of a population mixture of European and East Asian origin.   
 
Phenotypes found associated with more than one SNP include depressive slowed activity, 
interrupted sleep form depressive insomnia and depressive delusions of poverty, suggesting 
haplotype association.  Our results suggest a stronger association between NOS1AP and 
depression phenotypes in males diagnosed with schizophrenia.  However, as there are very 
few studies published in this area it is difficult to confirm a sex specific association.  A cross-
national study of sex differences in health covering depression suggested no significant 
overall sex differences in depression symptoms and they were only age and country-specific 
(Oksuzyan et al., 2010). 
 
In addition to depression, other studies have found association with specific schizophrenia 
phenotypes including hallucinations, delusions, avolition and social isolation (Kremeyer et 
al., 2009), obsessive-compulsive disorder and autism spectrum disorder (Delorme et al., 
2010).  It is not surprising that NOS1AP has such broad effects since NMDA receptor 
activation is a key component of the glutamate system which is implicated in diverse brain 
functions (Merritt et al., 2013).   
 
It is recognised that certain psychiatric conditions, like hallucinations, may lead to 
development of secondary phenotypes such as delusions and depression (Shiraishi et al., 
2014).  This raises the question of whether these non-depression phenotypes are directly due 
to NOS1AP dysfunction or secondary outcomes due to depression. 
 
The mode of action of NOS1AP in schizophrenia is thought to be via the inhibition of the 
downstream effects of the NMDA receptor on NO activity.  It is therefore thought that 
overexpression of NOS1AP short isoform due to the C-allele of rs1415263 may lead to 
schizophrenia development (Xu et al., 2005).  Other studies have suggested that association 
between the A allele of rs12742393 and schizophrenia is due to increased transcription factor 
binding and expression of NOS1AP mRNA (Wratten et al., 2009).  Studies of Brodmann’s 
Area 46 (a part of frontal cortex) in schizophrenia patients revealed that the pattern NOS1AP 
mRNA short isoform levels were increased while decreased levels were present in the 
cerebellum (Hadzimichalis et al., 2010).  Tissue culture studies led to the NOS1AP 
overexpression hypothesis in schizophrenia (Jaffrey et al., 1998) but animal studies suggested 
otherwise.  In these studies, NOS1AP was acting as a facilitator of NMDAR-mediated 
cellular cascades (Cheah et al., 2006; Fang et al., 2000; Li et al., 2013), which does not 
support the idea that NOS1AP overexpression could inhibit NMDAR-mediated NO 
production.  Given these inconsistencies, it is possible that the expression pattern of NOS1AP 
or its effects may vary in different regions of the brain. 
 
Excessive glutamate neurotransmission is thought to be associated with depression.  Our 
findings support a role for NOS1AP in depression in schizophrenia.  Evidence suggests that 
drugs that stimulate re-uptake of glutamate or inhibit glutamate activity exert antidepressant 
effects (Banasr et al., 2010; Gourley et al., 2012; Mineur et al., 2007).  A review of the role of 
NO in depression supports the positive correlation between NO levels and major depression, 
further strengthening the notion that depression is caused by excessive NO activity due to 
excessive glutamate neurotransmission (Dhir and Kulkarni, 2011). 
 
An interesting observation in our study is that rs1415259 is associated with sleep related 
depressive phenotypes, which has not previously been reported.  Stenberg observed that NO 
is an important factor for triggering recovery sleep after periods of sleep deprivation and 
inhibitors of NO synthase decrease spontaneous sleep (Stenberg, 2007).  This suggests a role 
for NOS1AP in the NO pathway which also affects sleeping patterns.  
 Out of the nine SNPs reported in the present study, only rs1415263 has previously been 
reported to have a functional role while the function of the other eight SNPs are yet to be 
confirmed.  SNP rs1415263 was associated with increased NOS1AP mRNA expression (Xu 
et al., 2005) and was in strong linkage equilibrium with another functional SNP that increases 
mRNA expression (Wratten et al., 2009). 
 
Multiple previous studies examining association between NOS1AP and schizophrenia 
revealed inconsistent results that failed to definitively establish a link between NOS1AP and 
schizophrenia.  Our study found only one SNP (rs1858232) that was marginally associated 
with schizophrenia and this association was not validated in a larger GWAS (Schizophrenia 
Working Group of the Psychiatric Genomics, 2014).  However, our positive association 
results between eight NOS1AP SNPs and multiple depression phenotypes within 
schizophrenia were consistent with the literature where numerous animal studies, phenotype 
association studies and molecular and pharmacological models strongly point towards a link 
between depression and NOS1AP. 
 
Limitations 
 
A meta-analysis looking at NOS1AP by Weber and colleagues (Weber et al., 2014) found that 
some NOS1AP SNPs are associated in smaller independent samples but are not associated in 
a larger pooled sample, possibly suggesting that there is population stratification in 
schizophrenia cohorts of different ethnic or geographical origin.  SNP-phenotype association 
results corrected for multiple testing suggest that many of our association findings may not 
pose significant effects and should be viewed with caution.  Although correction for multiple 
testing was performed we do not believe that it is totally appropriate to do so for these 
analyses as the multiple clinical measures do not represent independent variables, i.e. they are 
all depression measures that are likely to be related to one another.  Further replication 
studies of larger cohorts screened for appropriate phenotypes should be conducted to validate 
our association findings.  In addition, the function of NOS1AP SNPs, and correlation of NO-
NOS1AP mRNA levels should be studied to understand the role of NOS1AP in depression 
phenotypes of schizophrenia.  This should shed light on whether depression phenotypes share 
a common aetiology with schizophrenia due to NOS1AP function, or whether NOS1AP has a 
role in depression aetiology independent of its role in schizophrenia. 
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Tables 
Table 1: Participants’ demographic information. 
Demographic information 
Participants 
Schizophrenia Control 
Male 165 104 
Female 70 121 
Age in years: mean (±SD) 43.9 (10.7) 45 (13.2) 
Age of onset (±SD) 23.2 (6.3) 
Family with schizophrenia 
history 72  
Patients on medication 229 
Mean duration of first 
medication used in months 
(±SD) 
41.03 (42.96)a  
aLowest duration recorded is one month and highest duration recorded is more than eight 
years 
 
  
Table 2: Genotype counts and chi-square tests for association between rs1858232 and 
schizophrenia. 
Genotype Schizophrenia Control Likelihood ratio 
Trend test in a 
given directiona 
AA 125 135 
P = 0.041 P = 0.010 AG 87 75 
GG 22 9 
aExtended Mantel-Haenszel test for trend in a given direction 
 
Table 3: Genotype association of eight NOS1AP SNPs with depression measures in schizophrenia. 
Depression domain measure scoreab, ±SE 
SNP Genotypes (count) Slowed activity
c Poor appetitec Weight gainc Middle insomniad Early waking
c Excessive guiltc Delusions of povertyc 
rs1415259 
AA(59) 0.85, ±0.17 1.10, ±0.18 0.68, ±0.16 0.34, ±0.06 0.59, ±0.15 0.80, ±0.17 0.00, ±0.00 
AG(70) 0.86, ±0.16 0.84, ±0.16 0.59, ±0.14 0.16, ±0.04 0.16, ±0.08 1.07, ±0.16 0.00, ±0.00 
GG(23) 0.91, ±0.29 0.91, ±0.29 1.09, ±0.28 0.13, ±0.07 0.39, ±0.22 0.65, ±0.26 0.13, ±0.13 
F = 0.021 F = 0.608 F = 1.501 F = 3.841 F = 3.530 F = 1.177 F = 2.874 
P = 0.979 P = 0.546 P = 0.226 P = 0.024 P = 0.032 P = 0.311 P = 0.060 
 
Inheritance 
mode (P 
value) 
   A recessive (0.006) 
A recessive 
(0.016)   
rs1415263 
CC(50) 0.82, ±0.18 1.02, ±0.19 0.66, ±0.16 0.24, ±0.06 0.36, ±0.14 1.00, ±0.19 0.00, ±0.00 
CT(79) 0.63, ±0.13 0.91, ±0.15 0.75, ±0.14 0.20, ±0.05 0.42, ±0.11 0.92, ±0.15 0.00, ±0.00 
TT(28) 1.43, ±0.28 0.93, ±0.26 0.50, ±0.21 0.21, ±0.08 0.14, ±0.11 0.56, ±0.21 0.11, ±0.11 
F = 3.963 F = 0.104 F = 0.440 F = 0.125 F = 0.900 F = 1.083 F = 2.433 
    P = 0.021 P = 0.901 P = 0.645 P = 0.883 P = 0.409 P = 0.341 P = 0.091 
 
Inheritance 
mode (P 
value) 
C dominant 
(0.008)       
rs1858232 
AA(82) 0.80, ±0.15 1.05, ±0.15 0.67, ±0.13 0.26, ±0.05 0.39, ±0.11 0.83, ±0.14 0.04, ±0.04 
AG(62) 0.92, ±0.17 0.90, ±0.17 0.52, ±0.13 0.19, ±0.05 0.26, ±0.10 0.95, ±0.17 0.00, ±0.00 
GG(13) 0.62, ±0.33 0.54, ±0.31 1.46, ±0.42 0.08, ±0.08 0.54, ±0.31 0.92, ±0.40 0.00, ±0.00 
F = 0.330 F = 0.880 F = 3.444 F = 1.217 F = 0.640 F = 0.155 F = 0.448 
 P = 0.719 P = 0.417 P = 0.034 P = 0.299 P = 0.529 P = 0.857 P = 0.640 
 
Inheritance 
mode (P 
value) 
  G recessive (0.013)     
rs4531275 
CC(65) 0.77, ±0.16 1.12, ±0.17 0.60, ±0.14 0.26, ±0.06 0.34, ±0.12 0.91, ±0.16 0.00, ±0.00 
CT(75) 0.72, ±0.15 0.68, ±0.14 0.77, ±0.15 0.17, ±0.04 0.39, ±0.11 0.92, ±0.16 0.00, ±0.00 
TT(17) 1.59, ±0.37 1.47, ±0.37 0.53, ±0.29 0.24, ±0.11 0.24, ±0.18 0.63, ±0.30 0.19, ±0.19 
F = 3.274 F = 3.486 F = 0.501 F = 0.811 F = 0.189 F = 0.349 F = 4.577 
    P = 0.041 P = 0.033 P = 0.607 P = 0.446 P = 0.828 P = 0.706 P = 0.012 
 
Inheritance 
mode (P 
value) 
T recessive 
(0.012)      
T recessive 
(0.003) 
rs4656355 
AA(26) 0.92, ±0.28 0.85, ±0.26 0.77, ±0.24 0.19, ±0.08 0.23, ±0.16 0.62, ±0.24 0.12, ±0.12 
AG(67) 0.90, ±0.16 0.91, ±0.16 0.63, ±0.14 0.15, ±0.04 0.21, ±0.09 1.16, ±0.17 0.00, ±0.00 
GG(56) 0.84, ±0.17 1.05, ±0.18 0.68, ±0.17 0.34, ±0.06 0.57, ±0.15 0.77, ±0.17 0.00, ±0.00 
F = 0.044 F = 0.273 F = 0.133 F = 3.322 F = 2.631 F = 2.220 F = 2.410 
P = 0.957 P = 0.762 P = 0.875 P = 0.039 P = 0.075 P = 0.112 P = 0.093 
 
Inheritance 
mode (P 
value) 
   G recessive (0.012)    
rs4657178 
CC(89) 0.81, ±0.14 1.02, ±0.15 0.71, ±0.13 0.21, ±0.04 0.37, ±0.11 0.90, ±0.14 0.00, ±0.00 
CT(55) 0.80, ±0.17 0.76, ±0.17 0.62, ±0.16 0.22, ±0.06 0.33, ±0.12 0.84, ±0.18 0.00, ±0.00 
TT(13) 1.15, ±0.42 1.23, ±0.41 0.69, ±0.37 0.23, ±0.12 0.31, ±0.24 1.00, ±0.37 0.25, ±0.25 
F = 0.419 F = 0.955 F = 0.095 F = 0.010 F = 0.051 F = 0.088 F = 6.420 
    P = 0.658 P = 0.387 P = 0.909 P = 0.990 P = 0.950 P = 0.916 P = 0.002 
 
Inheritance 
mode (P 
value) 
      T recessive (0.0004) 
rs6683968 
GG(59) 0.80, ±0.17 1.08, ±0.18 0.64, ±0.15 0.29, ±0.06 0.32, ±0.12 0.90, ±0.17 0.00, ±0.00 
GT(78) 0.69, ±0.14 0.77, ±0.14 0.72, ±0.14 0.15, ±0.04 0.41, ±0.11 0.96, ±0.16 0.00, ±0.00 
TT(20) 1.50, ±0.34 1.25, ±0.33 0.60, ±0.28 0.25, ±0.10 0.20, ±0.16 0.53, ±0.26 0.16, ±0.16 
F = 3.150 F = 1.533 F = 0.107 F = 1.870 F = 0.445 F = 0.847 F = 3.732 
P = 0.046 P = 0.219 P = 0.898 P = 0.158 P = 0.642 P = 0.431 P = 0.026 
 
Inheritance 
mode (P 
value) 
T recessive 
(0.015)      
T recessive 
(0.007) 
rs6704393 CC(63) 0.76, ±0.16 1.02, ±0.17 0.57, ±0.14 0.24, ±0.05 0.44, ±0.13 0.86, ±0.16 0.00, ±0.00 
CT(67) 0.73, ±0.15 0.94, ±0.17 0.84, ±0.16 0.16, ±0.05 0.31, ±0.11 1.15, ±0.18 0.00, ±0.00 
TT(26) 1.19, ±0.29 0.85, ±0.26 0.54, ±0.22 0.27, ±0.09 0.23, ±0.16 0.31, ±0.16 0.12, ±0.12 
F = 1.285 F = 0.154 F = 1.000 F = 0.836 F = 0.580 F = 4.045 F = 2.530 
P = 0.280 P = 0.857 P = 0.370 P = 0.435 P = 0.561 P = 0.019 P = 0.083 
 
Inheritance 
mode (P 
value) 
     C dominant (0.013)  
aMeasure scores range from 0 to 1 and 0 to 3. 
bThirteen other depression measures were not shown as they are not associated with any of the SNPs in this study. 
cScores ranging from 0-3 
dScores ranging from 0-1 
 
